These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 29113708)

  • 41. The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis.
    Merza N; Akram M; Mengal A; Rashid AM; Mahboob A; Faryad M; Fatima Z; Ahmed M; Ansari SA
    Curr Probl Cardiol; 2023 May; 48(5):101602. PubMed ID: 36682393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S; Baker WL; White WB
    Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
    Herrera Comoglio R; Vidal Guitart X
    Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Wu S; Wang J; Guo S; Chai S; Yang Z; Li L; Zhang Y; Ji L; Zhan S
    Clin Ther; 2015 Jan; 37(1):225-241.e8. PubMed ID: 25554560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
    Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
    Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
    Alfayez OM; Almutairi AR; Aldosari A; Al Yami MS
    Can J Diabetes; 2019 Oct; 43(7):538-545.e2. PubMed ID: 31175007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
    Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
    Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.
    Li X; Song Y; Guo T; Xiao G; Li Q
    Diabetes Metab; 2022 Sep; 48(5):101366. PubMed ID: 35760374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
    Owens DR; Monnier L; Hanefeld M
    Diabetes Obes Metab; 2017 Dec; 19(12):1645-1654. PubMed ID: 28474401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Micro- and macrovascular outcomes in Type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis.
    Kress S; Kostev K; Dippel FW; Giani G; Rathmann W
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):821-9. PubMed ID: 22578200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.
    Kapoor I; Sarvepalli SM; D'Alessio D; Grewal DS; Hadziahmetovic M
    Surv Ophthalmol; 2023; 68(6):1071-1083. PubMed ID: 37454782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
    Heuvelman VD; Van Raalte DH; Smits MM
    Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
    Cariou B
    Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.